Beta- and Alpha-Cell Dysfunction in Type 2 Diabetes

 

 Buy Article Permissions and Reprints

Abstract

Insulin resistance is a common pathogenetic feature of type 2 diabetes. However, hyperglycemia would not develop if a concomitant defect in insulin secretion were not present. Impaired insulin secretion results from functional and survival defects of the β-cell. The functional defects can be demonstrated early in the natural history of diabetes and they are hallmarked by abnormal pulsatility of basal insulin secretion and loss of first-phase insulin release in response to a glucose challenge. Moreover, a significant reduction of the β-cell mass is apparent at the time of the diagnosis of diabetes. The progressive increase in glucose levels, that seems to characterize the natural history of type 2 diabetes, has been claimed to be largely due to progressive reduction of function and mass of β-cells. Although a genetic predisposition is likely to account for impaired insulin secretion, chronic exposure to hyperglycemia and high circulating FFA is likely to contribute to both functional and survival defects. The disturbance in the endocrine activity of the pancreas is not limited to insulin, since a concomitant increase in fasting plasma glucagon and impaired suppression after the ingestion of an oral glucose load are often observed. This alteration becomes prominent after the ingestion of a mixed meal, when plasma glucagon remains much higher in the diabetic patient as compared to normal individuals. The disproportionate changes in the plasma concentration of the two pancreatic hormones is clearly evident when the insulin:glucagon molar ratio is considered. It is the latter that mainly affects hepatic glucose production. Because of the reduction of the insulin:glucagon molar ratio basal endogenous glucose concentration will be higher causing fasting hyperglycemia, while the hepatic glucose output will not be efficiently suppressed after the ingestion of a meal, contributing to excessive post-prandial glucose rise. Correcting β- and α-cell dysfunction becomes, therefore, an attractive and rational therapeutic approach, particularly in the light of new treatments that may directly act on these pathogenetic mechanisms of type 2 diabetes.

References

• 1 The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus . Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus.  Diabetes Care. 2000;  23 (suppl. 1) S4-S19
  PubMedGoogle Scholar
• 2 DeFronzo R A, Bonadonna R C, Ferrannini E. Pathogenesis of NIDDM: a balanced overview.  Diabetes Care. 1992;  15 318-368
  CrossrefPubMedGoogle Scholar
• 3 UKPDS Group, UK Prospective Diabetes Study 16 . Overview of six years’ therapy of type 2 diabetes - a progressive disease.  Diabetes. 1995;  44 1249-1258
  CrossrefPubMedGoogle Scholar
• 4 O’Rahilly S, Turner R C, Matthews D R. Impaired pulsatile secretion of insulin in relatives of patients with non-insulin-dependent diabetes.  N Engl J Med. 1988;  318 1225-1230
  PubMedGoogle Scholar
• 5 Bergman R N, Finegood D T, Kahn S E. The evolution of beta-cell dysfunction and insulin resistance in type 2 diabetes.  Eur J Clin Invest. 2002;  32 (Suppl 3) 35-45
  PubMedGoogle Scholar
• 6 Pradhan A D, Manson J E, Meigs J B, Rifai N, Buring J E, Liu S, Ridker P M. Insulin, proinsulin, proinsulin: insulin ratio, and the risk of developing type 2 diabetes mellitus in women.  Am J Med. 2003;  114 438-444
  CrossrefPubMedGoogle Scholar
• 7 Hayden M R. Islet amyloid, metabolic syndrome, and the natural progressive history of type 2 diabetes mellitus.  JOP. 2002;  3 126-138
  PubMedGoogle Scholar
• 8 Avogaro A, Crepaldi C, Miola M, Maran A, Pengo V, Tiengo A, Del P rato. High blood ketone body concentration in type 2 non-insulin dependent diabetic patients.  J Endocrinol Invest. 1996;  19 99-105
  PubMedGoogle Scholar
• 9 Maruyama H, Hisatomi A, Orci L, Grodsky G M, Unger R H. Insulin within islets is a physiologic glucagon release inhibitor.  J Clin Invest. 1984;  74 2296-2299
  CrossrefPubMedGoogle Scholar
• 10 Dimitriadis G D, Pehling G B, Gerich J E. Abnormal glucose modulation of islet A- and B-cell responses to arginine in non-insulin-dependent diabetes mellitus.  Diabetes. 1985;  34 541-54
  PubMedGoogle Scholar
• 11 Groop L C, Bonadonna R C, Del Prato S, Ratheiser K, Zyck K, Ferrannini E, DeFronzo R A. Glucose and free-fatty acid metabolism in non-insulin-dependent diabetes: evidence for multiple insulin resistance.  J Clin Invest. 1989;  84 205-213
  CrossrefPubMedGoogle Scholar
• 12 Reaven G M, Chen Y D, Golay A, Swislocki A L, Jaspan J B. Documentation of hyperglucagonemia throughout the day in nonobese and obese patients with noninsulin-dependent diabetes mellitus.  J Clin Endocrinol Metab. 1987;  64 106-110
  CrossrefPubMedGoogle Scholar
• 13 Unger R H, Aguilar-Parada E, Muller W A, Eisentraut A M. Studies of pancreatic alpha cell function in normal and diabetic subjects.  J Clin Invest. 1970;  49 837-848
  PubMedGoogle Scholar
• 14 Baron A D, Schaeffer L, Shragg P, Kolterman O G. Role of hyperglucagonemia in maintenance of increased rates of hepatic glucose output in type II diabetics.  Diabetes. 1987;  36 274-283
  CrossrefPubMedGoogle Scholar
• 15 Gastaldelli A, Baldi S, Pettiti M, Toschi E, Camastra S, Natali A, Landau B R, Ferrannini E. Influence of obesity and type 2 diabetes on gluconeogenesis and glucose output in humans: a quantitative study.  Diabetes. 2000;  49 1367-1373
  CrossrefPubMedGoogle Scholar
• 16 Del Prato S, Castellino P, Simonson D C, DeFronzo R A. Hyperglucagonemia and insulin-mediated glucose metabolism.  J Clin Invest. 1987;  79 547-55
  PubMedGoogle Scholar
• 17 Del Prato S, Vigili de Kreutzenberg S, Riccio A. et al . Partial recovery of insulin secretion and action after combined insulin-sulfonylurea treatment in type 2 (non-insulin-dependent) diabetic patients with secondary failure to oral agents.  Diabetologia. 1990;  33 688-695
  CrossrefPubMedGoogle Scholar
• 18 D’Alessio D A, Vahl T P. Glucagon-like peptide 1: evolution of an incretin into a treatment for diabetes.  Am J Physiol Endocrinol Metab. 2004;  286 E882-E890
  CrossrefPubMedGoogle Scholar
• 19 Rachman J, Barrow B A, Levy J C, Turner R C. Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM.  Diabetologia. 1997;  40 205-211
  CrossrefPubMedGoogle Scholar
• 20 Kolterman O G, Buse J B, Fineman M S, Gaines E, Heintz S, Bicsak T A, Taylor K, Kim D, Aisporna M, Wang Y, Baron A D. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes.  J Clin Endocrinol Metab. 2003;  88 3082-3089
  CrossrefPubMedGoogle Scholar
• 21 Ahren B, Simonsson E, Larsson H, Landin-Olsson M, Torgeirsson H, Jansson P A, Sandqvist M, Bavenholm P, Efendic S, Eriksson J W, Dickinson S, Holmes D. Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes.  Diabetes Care. 2002;  25 869-875
  PubMedGoogle Scholar
• 22 Del Prato S, Tiengo A. The importance of first-phase insulin secretion: implications for the therapy of type 2 diabetes mellitus.  Diabetes Metab Res Rev. 2001;  17 164-174
  CrossrefPubMedGoogle Scholar
• 23 Del Prato S, Marchetti P, Bonadonna R C. Phasic insulin release and metabolic regulation in type 2 diabetes.  Diabetes. 2002;  51 (Suppl 1) S109-S116
  CrossrefPubMedGoogle Scholar
• 24 Cretti A, Lehtovirta M, Bonora E, Brunato B, Zenti M G, Tosi F, Caputo M, Caruso B, Groop L C, Muggeo M, Bonadonna R C. Assessment of beta-cell function during the oral glucose tolerance test by a minimal model of insulin secretion.  Eur J Clin Invest. 2001;  31 405-416
  CrossrefPubMedGoogle Scholar
• 25 Haffner S M, Miettinen H, Gaskill S P, Stern M. Decreased insulin action and insulin secretion predict the development of impaired glucose tolerance.  Diabetologia. 1996;  39 1201-1207
  PubMedGoogle Scholar
• 26 Kosaka K, Kuzuya T, Hagura R, Yoshinaga H. Insulin response to oral glucose load is consistently decreased in established non-insulin-dependent diabetes mellitus: the usefulness of decreased early insulin response as a predictor of non-insulin-dependent diabetes mellitus.  Diabet Med. 1996;  13 S109-S119
  PubMedGoogle Scholar
• 27 Weyer C, Bogardus C, Mott D M, Pratley R E. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus.  J Clin Invest. 1999;  104 787-794
  CrossrefPubMedGoogle Scholar
• 28 Weyers C, Tataranni P A, Bogardus C, Prately R E. Insulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose tolerance during each stage of Type 2 diabetes development.  Diabetes Care. 2000;  24 89-94
  PubMedGoogle Scholar
• 29 Larsson H, Ahren B. Islet dysfunction in insulin resistance involves impaired insulin secretion and increased glucagon secretion in postmenopausal women with impaired glucose tolerance.  Diabetes Care. 2000;  23 650-657
  PubMedGoogle Scholar
• 30 Ohneda A, Watanabe K, Horigome K, Sakai T, Kai Y, Oikawa S. Abnormal response of pancreatic glucagon to glycemic changes in diabetes mellitus.  J Clin Endocrinol Metab. 1978;  46 504-510
  PubMedGoogle Scholar
• 31 Mitrakou A, Kelley D, Veneman T, Jenssen T, Pangburn T, Reilly J, Gerich J. Contribution of abnormal muscle and liver glucose metabolism to postprandial hyperglycemia in NIDDM.  Diabetes. 1990;  39 1381-1390
  PubMedGoogle Scholar
• 32 Mitrakou A, Kelley D, Mokan M. et al . Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance.  N Engl J Med. 1992;  326 22-29
  PubMedGoogle Scholar
• 33 Bruttomesso D, Pianta A, Mari A, Valerio A, Marescotti M-C, Avogaro A, Tiengo A, Del Prato S. Restoration of early rise in plasma insulin levels improves the glucose tolerance of type 2 diabetic patients.  Diabetes. 1999;  48 99-105
  CrossrefPubMedGoogle Scholar
• 34 Gerich J E, Lorenzi M, Karam J H, Schneider V, Forsham P H. Abnormal pancreatic glucagon secretion and postprandial hyperglycemia in diabetes mellitus.  JAMA. 1975;  234 159-155
  CrossrefPubMedGoogle Scholar
• 35 Taylor R, Magnusson I, Rothman D L, Cline G W, Caumo A, Cobelli C, Shulman G I. Direct assessment of liver glycogen storage by 13C nuclear magnetic resonance spectroscopy and regulation of glucose homeostasis after a mixed meal in normal subjects.  J Clin Invest. 1996;  97 126-132
  PubMedGoogle Scholar
• 36 Ferrannini E, Simonson D C, Katz L D, Reichard G Jr., Bevilacqua S, Barrett E J, Olsson M, DeFronzo R A. The disposal of an oral glucose load in patients with non-insulin-dependent diabetes.  Metabolism. 1988;  37 79-85
  CrossrefPubMedGoogle Scholar
• 37 Matsuda M, Defronzo R A, Glass L, Consoli A, Giordano M, Bressler P, Delprato S. Glucagon dose-response curve for hepatic glucose production and glucose disposal in type 2 diabetic patients and normal individuals.  Metabolism. 2002;  51 1111-1119
  CrossrefPubMedGoogle Scholar
• 38 Dornhorst A. Insulinotropic meglitinide analogues.  Lancet. 2001;  358 1709-1716
  CrossrefPubMedGoogle Scholar
• 39 Jiang G, Zhang B B. Glucagon and regulation of glucose metabolism.  Am J Physiol Endocrinol Metab. 2003;  284 E671-E678
  PubMedGoogle Scholar
• 40 Drucker D J. Enhancing incretin action for the treatment of type 2 diabetes.  Diabetes Care.. 2003;  26 2929-2940
  CrossrefPubMedGoogle Scholar
• 41 Wiedeman P E, Trevillyan J M. Dipeptidyl peptidase IV inhibitors for the treatment of impaired glucose tolerance and type 2 diabetes.  Curr Opin Investig Drugs. 2003;  4 412-420
  PubMedGoogle Scholar
• 42 Deng S, Vatamaniuk M, Huang X, Doliba N, Lian M M, Frank A, Velidedeoglu E, Desai N M, Koeberlein B, Wolf B, Barker C F, Naji A, Matschinsky F M, Markmann J F. Structural and functional abnormalities in the islets isolated from type 2 diabetic subjects.  Diabetes. 2004;  53 624-632
  PubMedGoogle Scholar
• 43 Yoon K H, Ko S H, Cho J H, Lee J M, Ahn Y B, Song K H, Yoo S J, Kang M I, Cha B Y, Lee K W, Son H Y, Kang S K, Kim H S, Lee I K, Bonner-Weir S. Selective beta-cell loss and alpha-cell expansion in patients with type 2 diabetes mellitus in Korea.  J Clin Endocrinol Metab. 2003;  88 2300-2308
  CrossrefPubMedGoogle Scholar
• 44 Butler A E, Janson J, Bonner-Weir S, Ritzel R, Rizza R A, Butler P C. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes.  Diabetes. 2003;  52 102-110
  CrossrefPubMedGoogle Scholar
• 45 Del Prato S, Wishner W J, Gromada J, Schluchter B J. Beta-cell mass plasticity in type 2 diabetes.  Diabetes Obes Metab. 2004;  6 319-331
  CrossrefPubMedGoogle Scholar
• 46 Vinik A, Pittenger G, Rafaeloff R, Rosenberg L, Duguid W. Determinants of pancreatic islet cell mass: a balance between neogenesis and senescence/apoptosis.  Diabetes Rev. 1996;  4 235-263
  PubMedGoogle Scholar
• 47 Kloppel G, Lohr M, Habich K, Oberholzer M, Heitz P U. Islet pathology and the pathogenesis of type 1 and type 2 diabetes mellitus revisited.  Surv Synth Pathol Res. 1985;  4 110-125
  PubMedGoogle Scholar
• 48 Bagust A, Beale S. Deteriorating beta-cell function in type 2 diabetes: a long-term model.  QJM. 2003;  96 281-288
  CrossrefPubMedGoogle Scholar
• 49 Leahy J L, Bonner-Weir S, Weir G C. Beta-cell dysfunction induced by chronic hyperglycemia. Current ideas on mechanism of impaired glucose-induced insulin secretion.  Diabetes Care. 1992;  15 442-455
  PubMedGoogle Scholar
• 50 Robertson R P, Harmon J, Tran P O, Poitout V. Beta-cell glucose toxicity, lipotoxicity, and chronic oxidative stress in type 2 diabetes.  Diabetes. 2004;  53 (Suppl 1) S119-S124
  PubMedGoogle Scholar
• 51 Del Prato S, Leonetti F, Simonson D C, Sheehan P, Matsuda M, DeFronzo R A. Effect of sustained physiologic hyperinsulinaemia and hyperglycaemia on insulin secretion and insulin sensitivity in man.  Diabetologia. 1994;  37 1025-1035
  PubMedGoogle Scholar
• 52 Marchetti P, Lupi R, Federici M, Marselli L, Masini M, Boggi U, Del Guerra S, Patane G, Piro S, Anello M, Bergamini E, Purrello F, Lauro R, Mosca F, Sesti G, Del Prato S. Insulin secretory function is impaired in isolated human islets carrying the Gly(972)→Arg IRS-1 polymorphism.  Diabetes. 2002;  51 1419-1424
  PubMedGoogle Scholar
• 53 Sesti G, Cardellini M, Marini M A, Frontoni S, D’Adamo M, Del Guerra S, Lauro D, De Nicolais P, Sbraccia P, Del Prato S, Gambardella S, Federici M, Marchetti P, Lauro R. A common polymorphism in the promoter of UCP2 contributes to the variation in insulin secretion in glucose-tolerant subjects.  Diabetes. 2003;  52 1280-1283
  PubMedGoogle Scholar
• 54 Del Guerra S, Lupi R, Bugliani M, Sbrana S, Torri S, Boggi U, Vistoli F, Mosca F, Del Prato S, Marchetti P. Functional characterization of pancreatic islets isolated from Type 2 diabetic donors.  Diabetologia. 2004;  47 (Suppl. 1) A27
  PubMedGoogle Scholar
• 55 McGarry J D, Dobbins R L. Fatty acids, lipotoxicity and insulin secretion.  Diabetologia. 1999;  42 128-138
  CrossrefPubMedGoogle Scholar
• 56 Gravena C, Mathias P C, Ashcroft S J. Acute effects of fatty acids on insulin secretion from rat and human islets of Langerhans.  J Endocrinol. 2002;  173 73-80
  CrossrefPubMedGoogle Scholar
• 57 Lupi R, Dotta F, Marselli L, Del Guerra S, Masini M, Santangelo C, Patane G, Boggi U, Piro S, Anello M, Bergamini E, Mosca F, di Mario U, Del Prato S, Marchetti P. Prolonged exposure to free fatty acids has cytostatic and pro-apoptotic effects on human pancreatic islets: evidence that beta-cell death is caspase mediated, partially dependent on ceramide pathway, and Bcl-2 regulated.  Diabetes. 2002;  51 1437-1442
  CrossrefPubMedGoogle Scholar
• 58 Prentki M, Joly E, El-Assaad W, Roduit R. Malonyl-CoA signaling, lipid partitioning, and glucolipotoxicity: role in beta-cell adaptation and failure in the etiology of diabetes.  Diabetes. 2002;  51 (Suppl 3) S405-S413
  CrossrefPubMedGoogle Scholar
• 59 Ostgren C J, Lindblad U, Ranstam J, Melander A, Rastam L,. Skaraborg hypertension and Diabetees Project . Glycaemic control, disease duration and beta-cell function in patients with Type 2 diabetes in a Swedish community. Skaraborg Hypertension and Diabetes Project.  Diabet Med. 2002;  19 125-129
  CrossrefPubMedGoogle Scholar
• 60 Lupi R, Del Guerra S, Marselli L, Bugliani M, Boggi U, Mosca F, Marchetti P, Del Prato S. Rosiglitazone prevents the impairment of human islet function induced by fatty acids: evidence for a role of PPARgamma2 in the modulation of insulin secretion.  Am J Physiol Endocrinol Metab. 2004;  286 E560-E567
  CrossrefPubMedGoogle Scholar
• 61 Finegood D T, McArthur M D, Kojwang D, Thomas M J, Topp B G, Leonard T, Buckingham R E. Beta-cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death.  Diabetes. 2001;  50 1021-1029
  PubMedGoogle Scholar
• 62 List J F, Habener J F. Glucagon-like peptide 1 agonists and the development and growth of pancreatic beta-cells.  Am J Physiol Endocrinol Metab. 2004;  286 E875-E581
  CrossrefPubMedGoogle Scholar

Dr. S. Del Prato

Department of Endocrinology and Metabolism, Section of Diabetes, Ospedale Cisanello

Via Paradisa 2 · Pisa 56124 · Italy

Phone: +39-050995103

Fax: +39050541521 ·

Email: delprato@immr.med.unipi.it